Antihyperlipidemic Drugs Market Size, Competitive Landscape and Market Forecast - 2029

SKU: DMPH2830 | Last Updated On: Jun 23 2022 | Available Formats

> Global Antihyperlipidemic Drugs Market Expected to reach a high CAGR during the forecast period 2022-2029: DataM Intelligence

Global Antihyperlipidemic Drugs Market is segmented By Drug Class (Statins, PCSK9 Inhibitors, Bile Acid Sequestrants, Cholesterol Absorption Inhibitors, Fibric Acid Derivatives, Combination, Symptoms Check), By Route of Administration (Oral, Intravenous), By Distribution Channel (Hospital Pharmacy, Pharmacy Stores, Other), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2022-2029


Market Overview

The Global "Antihyperlipidemic Drugs Market" is estimated to reach at a CAGR during the forecast period (2022-2029).  

Antihyperlipidemic drugs are medications that act to lower levels of lipids in the blood, addressing dangerously high cholesterol and reducing the risks of conditions like cardiopulmonary artery disease. These compounds are also known as hypolipidemic or lipid-lowering drugs, all reference to their primary function in the body. These drugs can inhibit absorption, encourage the body to eliminate more lipids in the feces, and boost levels of good cholesterol to lower bad cholesterol.


Market Dynamics

The global antihyperlipidemic drugs market growth is driven by the rise in the incidence of disorders related to distributed cholesterol levels in the blood also contributes. Moreover, the surge in awareness regarding complications related to hyperlipidemia is another major factor that fuels the growth of the market.

The increasing prevalence of cardiovascular diseases is expected to drive the growth in the forecast period

The increasing prevalence of cardiovascular diseases, hypertension, coronary artery disease, and heterozygous hypercholesterolemia all over the world is driving the global antihyperlipidemic combination drugs market. Extensive research and development of antihypelipidemic combination drugs are also anticipated to fuel the market in the near future.

A total cholesterol level of 170mg/dl or less is acceptable, 170 to 199mg/dl is borderline, and 200mg/dl or more is high. According to the American Heart Association, cholesterol levels steadily increase after 20 years of age. They normally decline after the age of 70 in women and 60 in men.

Additionally, women of all ages tend to have about 10mg/dl higher mean HDL-C levels as compared to men of all ages. High cholesterol in the blood increases the risk of myocardial infarction and stroke. Thus, hypercholesterolemia increases susceptibility to CVD. Hyperlipidemia is associated with other major comorbidities such as diabetes type II and chronic kidney disease. According to the World Health Organization (WHO), hypercholesterolemia is estimated to result in more than 2.6 million deaths each year.

Almost 37.0% of adults in the U.S. have high LDL-C levels. Yet, lesser than 50.0% of patients receive any form of treatment and approximately 33.0% of patients undergoing treatment are unable to achieve normal lipid levels. The market is anticipated to grow modestly during the forecast period.

Increase in hyperlipidemia cases expected to drive the market growth

The global antihyperlipidemic drugs market is anticipated to expand during the forecast period due to the increase in hyperlipidemia cases. The primary cause of hyperlipidemia is lifestyle habits or medical conditions. Obesity, smoking, and lack of exercise are lifestyle habits that are expected to lead to hyperlipidemia. Medical conditions that are likely to result in hyperlipidemia are kidney disease, diabetes, pregnancy, etc. The global antihyperlipidemic drugs market is expected to expand due to the increase in the elderly population and the incidence of cardiovascular diseases. According to the European Society of Cardiology (ESC) there are more than 11 million new cases of cardiovascular diseases in Europe and more than six million new cases in the European Union. Moreover, according to the report by faculties of the Department of Nutrition and Health Sciences, University Putra Malaysia, by 2020, cardiovascular diseases are expected to account for seven out of every 10 deaths in developing countries.

Regulatory obstruction is likely to hinder the market growth

However, the high cost of the treatment and stringent government regulations and policies related to drug patents may restrict the growth of the market.


COVID-19 Impact Analysis

COVID-19 was originally thought to be a virus impacting the lungs, but it is now clear that it can also impact and cause damage to the heart, with a higher risk of complications for the many patients worldwide who already have heart disease or are at increased risk. Cardiovascular complications are frequent among COVID-19 patients and might contribute to adverse clinical events and mortality, together with pre-existing cardiovascular comorbidities and RF. Clinicians worldwide should be aware of this association, to identify patients at higher risk. Impact of cardiovascular risk profile on COVID-19 outcome. Thus the rising prevalence of the disease among CVD patients will drive the growth of antihyperlipidemic drugs in the forecast period.

Segment Analysis

Statins segment is expected to grow at the fastest CAGR during the forecast period (2021-2028)

The statins drugs are expected to hold the largest market share owing to several significant advantages such as it reduce the risk associated with heart attacks which is another major factor that contributes to the growth of the market.  

Statins are lipid-lowering agents or medications used in the treatment of high lipid levels. These are often referred to as high cholesterol found in the blood. The major function of statins is to lower blood cholesterol and prevent atherosclerosis. These drugs help to prevent heart attacks and strokes. These lower the production of cholesterol by blocking an enzyme known as HMG-CoA reductase used by the liver. According to studies, statins have reduced heart attacks and strokes by 25% to 35%. Statins recommended by health care practitioners work well for patients with balanced nutritious food and exercise. Healthy lifestyle practices are essential to improve the quality of the patient’s life.

An increase in the patient population suffering from obesity, cardiovascular diseases, and diabetes propels the demand for statins across the globe. Demand for effective treatment to reduce LDL cholesterol is also a major factor driving the global statins market. Cholesterol awareness campaigns and technologically advanced health care facilities increase the demand for statins. Companies are expanding their market presence across the globe by establishing strong distribution networks, especially in developing countries.

Additionally, the growing adoption of combination therapies that use statin with other cholesterol diminishing compounds, such as ezetimibe, is acting as another growth-inducing factor. Research has found statin-ezetimibe combination therapy to be capable of achieving near-normal lipid profiles in familial hypercholesterolemia patients and significantly reducing the risk of CVDs occurrence. Other factors, including improving healthcare infrastructure and growing health consciousness among consumers, are projected to drive the market.

The hospital pharmacy is expected to dominate the Antihyperlipidemic drugs market during the forecast period

The hospital pharmacies held the largest share in the antihyperlipidemic drugs market. This is mainly owing to the increasing number of patients suffering from conditions that are treated in hospitals equipped with advanced infrastructure and adequate facilities. Moreover, the growing number of hospitals along with adequate reimbursement policies is also contributing to the growth of this segment.


Geographical Analysis

North America region holds the largest market share global antihyperlipidemic drugs market

North America region is dominating the global antihyperlipidemic drugs market accounted for the largest market share in 2019. The rising prevalence of vascular diseases and the number of amputations in the region are likely to augment the antihyperlipidemic drugs market in North America. Expansion of the market in North America can also be attributed to substantial investments in R&D and healthcare expenditure by governments and private players operating in the field of prosthetics in the region.

Hyperlipidemia guidelines in the U.S. are playing an imperative role in the growth of the market as they address the dosage regimen of statins, which include patients aged 21 years and above suffering from the risk of developing Atherosclerotic Cardiovascular Disease (ASCVD). As a result, the target population for statins is expanding to other comorbidities of high cholesterol and triglyceride levels. Most antihyperlipidemic drugs have minor adverse effects. However, some drugs are likely to cause serious adverse effects such as liver damage or type 2 diabetes. Drug classes such as CETP inhibitors have been withdrawn or discontinued even in the later stages of trials due to adverse effects or failure to achieve satisfactory results. Risks associated with antihyperlipidemic pose a major challenge to their entry into the market.


Competitive Landscape

The antihyperlipidemic drugs market is moderately competitive with the presence of local as well as global companies.  Some of the key players which are contributing to the growth of the market include Sanofi S.A, Boehringer Ingelheim GmbH, Merck KGaA, Johnson and Johnson, Bayer AG, Pfizer, Inc. Takeda Pharmaceutical Co., Ltd., AstraZeneca plc, Daiichi Sankyo Company, Sanofi S.A., and Novartis International AG., among others. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the antihyperlipidemic drugs market globally.   

Antihyperlipidemic Drugs Market Key Companies to Watch

Sanofi S.A

Overview: Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. Its segments are Pharmaceuticals, Human Vaccines (Vaccines), and Others. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Specialty Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production, and marketing activities for all of the Company's pharmaceuticals operations.

Product Portfolio: The Company’s portfolio is comprised of drugs, generic medicines, food supplements, cosmetics, and medical devices such as cancer, cardiology, gynecology, and diabetes.

The global antihyperlipidemic drugs market report would provide access to an approx. 61 market data tables, 55 figures, and 180 pages.

Trending Topics

Stargardt Disease Therapeutics Market

Lipid-regulating Drugs Market

Hedgehog pathway inhibitors Market

Did not find what you were looking for?Every 7 out of 10 customers request tailored reports. Get yours today!
We collate your requirements.
Our global research team is put into action.
We deliver, and make sure your endeavour is a success!

Buy This Report

20% Discount Applied*

Note*: For "Bundle/Bulk" Subscription of Reports,
please contact: [email protected]

Get your free sample proposal with a single click!